Vincent  Chen

Dr. Vincent Chen

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2019 in Cancers
Verified
Journal Article
Open access
PDF file
MVMaxence Le Vasseur
Maxence Le Vasseur
VVincent Chen
Vincent Chen
KHKate Huang
Kate Huang
WVWayne A. Vogl
Wayne A. Vogl
CNChristian C. Naus
Christian C. Naus
Endomembrane specialization allows functional compartmentalization but imposes physical constraints to information flow within the cell. However, the evolution of an endomembrane system was associated with the emergence of contact sites facilitating communication between membrane-bound organelles. Contact sites between the endoplasmic reticulum (ER) and mitochondria are highly conserved in terms of their morphological features but show surprising molecular diversity within and across eukaryote species. ER-mitochondria contact sites are thought to regulate key processes in oncogenesis but their molecular composition remains poorly characterized in mammalian cells. In this study, we investigate the localization of pannexin 2 (Panx2), a membrane channel protein showing tumor-suppressing properties in cancer cells. Using a combination of subcellular fractionation, particle tracking in live-cell, and immunogold electron microscopy, we show that Panx2 localizes at ER-mitochondria contact sites in mammalian cells and sensitizes cells to apoptotic stimuli.

19 March 2019 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
QAQurratulain Aftab
Qurratulain Aftab
Marc MESNILMarc MESNIL
Marc MESNIL
EOEmmanuel Ojefua
Emmanuel Ojefua
APAlisha Poole
Alisha Poole
JNJenna Noordenbos
Jenna Noordenbos
VVincent Chen
Vincent Chen
Extracellular matrix (ECM) remodeling, degradation and glioma cell motility are critical aspects of glioblastoma multiforme (GBM). Despite being a rich source of potential biomarkers and targets for therapeutic advance, the dynamic changes occurring within the extracellular environment that are specific to GBM motility have yet to be fully resolved. The gap junction protein connexin43 (Cx43) increases glioma migration and invasion in a variety of in vitro and in vivo models. In this study, the upregulation of Cx43 in C6 glioma cells induced morphological changes and the secretion of proteins associated with cell motility. Demonstrating the selective engagement of ECM remodeling networks, secretome analysis revealed the near-binary increase of osteopontin and matrix metalloproteinase-3 (MMP3), with gelatinase and NFF-3 assays confirming the proteolytic activities. Informatic analysis of interactome and secretome downstream of Cx43 identifies networks of glioma motility that appear to be synergistically engaged. The data presented here implicate ECM remodeling and matrikine signals downstream of Cx43/MMP3/osteopontin and ARK1B10 inhibition as possible avenues to inhibit GBM.

14 April 2023 in Heliyon
Verified
Journal Article
Open access
RFRiley Feser
Riley Feser
ROReid M. Opperman
Reid M. Opperman
BNBraydon Nault
Braydon Nault
SMSujit Maiti
Sujit Maiti
VVincent Chen
Vincent Chen
Mousumi MajumderMousumi Majumder
Mousumi Majumder
MicroRNA (miRNA/miR) 526 b- and miR655-overexpressed tumor cell-free secretions regulate the breast cancer tumor microenvironment (TME) by promoting tumor-associated angiogenesis, oxidative stress, and hypoxic responses. Additionally, premature miRNA (pri-miR526b and pri-miR655) are established breast cancer blood biomarkers. However, the mechanisms of how these miRNAs regulate the TME has yet to be investigated. Mass spectrometry analysis of miRNA-overexpressed cell lines MCF7-miR526b, MCF7-miR655, and miRNA-low MCF7-Mock cell-free secretomes identified 34 differentially expressed proteins coded by eight genes. In both miRNA-high cell secretomes, four markers are upregulated: YWHAB, SFN, TXNDC12, and MYL6B, and four are downregulated: PEA15, PRDX4, PSMB6, and FN1. All upregulated marker transcripts are significantly high in both total cellular RNA pool and cell-free secretions of miRNA-high cell lines, validated with quantitative RT-PCR. Bioinformatics tools were used to investigate these markers' roles in breast cancer. These markers' top gene ontology functions are related to apoptosis, oxidative stress, membrane transport, and motility supporting oncogenic miR526b- and miR655-induced functions. Gene transcription factor analysis tools were used to show how these miRNAs regulate the expression of each secretory marker. Data extracted from the Human Protein Atlas showed that YWHAB, SFN, and TXNDC12 expression could distinguish early and late-stage breast cancer in various breast cancer subtypes and are associated with poor patient survival. Additionally, immunohistochemistry analysis showed the expression of each marker in breast tumors. A stronger correlation between miRNA clusters and upregulated secretory markers gene expression was found in the luminal A tumor subtype. YWHAB, SFN, and MYL6B are upregulated in breast cancer patient's blood, showing biomarker potential. Of these identified novel miRNA secretory markers, SFN and YWHAB successfully passed all validations and are the best candidates to further investigate their roles in miRNA associated TME regulation. Also, these markers show the potential to serve as blood-based breast cancer biomarkers, especially for luminal-A subtypes.

1 January 2020 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
APAlisha T. Poole
Alisha T. Poole
CSChristopher A. Sitko
Christopher A. Sitko
CLCaitlin Le
Caitlin Le
CNChristian C. Naus
Christian C. Naus
BHBryan M. Hill
Bryan M. Hill
VVincent Chen
Vincent Chen
Glioblastoma multiforme (GBM) is the deadliest and the most common primary malignant brain tumour. The median survival for patients with GBM is around one year due to the nature of glioma cells to diffusely invade that make the complete surgical resection of tumours difficult. Based upon the connexin43 (Cx43) model of glioma migration we have developed a computational framework to evaluate MMP inhibition in materials relevant to GBM. Using the ilomastat Leu-Trp backbone, we have synthesised novel sulphonamides and monitored the performance of these compounds in conditioned media expressing MMP3. From the results discussed herein we demonstrate the performance of sulfonamide based MMPIs included AP-3, AP-6, and AP-7.

26 May 2022
Verified
Book Chapter
Closed access
PDF file
RHRafe Helwer
Rafe Helwer
VVincent Chen
Vincent Chen

17 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
CGCorbin Glufka
Corbin Glufka
EOEmmanuel Ojefua
Emmanuel Ojefua
LFLeonard J. Foster
Leonard J. Foster
WSWun Chey Sin
Wun Chey Sin
CNChristian C. Naus
Christian C. Naus
VVincent Chen
Vincent Chen
Glioblastoma is among the most aggressive primary brain tumors, with the invasion of surrounding tissue driven by coordinated remodeling of the extracellular matrix (ECM) by proteolytic enzymes, including the matrix metalloproteinase (MMP) family. The gap junction protein connexin43 (Cx43) has emerged as an unexpected promoter of this invasive phenotype. However, the downstream molecular mechanisms linking Cx43 to ECM proteolysis remain poorly understood. We previously demonstrated selective upregulation of MMP3 within the secretome of Cx43-overexpressing glioma cells, implicating Cx43 in the regulation of ECM protease activity. To identify the molecular intermediaries responsible, we carried out a proteomic survey of gap junction (GJ)-associated signaling networks. Amongst these, we identified a Cx43 protein-protein interaction involving annexin A2 (ANXA2), a known regulator of ECM proteases. SDS-PAGE/Western blot and confocal imaging demonstrated that elevated Cx43 expression drives selective recruitment of ANXA2 to gap junction membranes, forming a junctional signaling platform rather than increasing total ANXA2 abundance. This recruitment coincided with co-localization of S100A10, suggesting assembly of an intact ANXA2/S100A10 complex at gap junctions. Using ANXA2-mimetic peptides targeting the S100A10-binding domain, we demonstrate that disruption of the ANXA2/S100A10 complex leads to a significant reduction in MMP3 activity. Furthermore, in 3D spheroids grown in ECM-replicating gels, ANXA2 peptide treatment significantly reduced the invasive potential of C6-13 (Cx43-overexpressing) cells. Together, these data define a novel Cx43→ANXA2→S100A10→MMP3 signaling axis, advancing our understanding of ECM remodeling in glioblastoma and establishing the ANXA2/S100A10 complex as a promising therapeutic target for disrupting Cx43-driven glioblastoma progression.